Europe Antibodies Industry value worth $ 44.126 Billion by 2021Posted by rohan on October 23rd, 2017 According to the report Europe Antibodies Industry, published by Market Data Forecast, The Industry was worth $ 25.708 Billion in 2016 and estimated to reach $ 44.126 Billion by the end of 2021 with a growing potential of 11.41 %. Efficient resource to therapy of complex disorders with minor side-effects has enhanced the growth of antibodies based therapeutics against chemical drugs. Antibodies (Ab’s) are also known as an immunoglobulin (Ig) that are large, Y-shaped protein produced by plasma cells which are used by the immune system to detect, identify and neutralize pathogens such as Viruses and bacteria. The antibody recognizes harmful agent, called an antigen, via the Fab's variable region. Depending on the type of antigen, the binding may inhibit the biological process causing the disease or could activate macrophages to destroy the foreign substance. Browse Industry data tables and in-depth TOC of the Europe Antibodies Industry to 2021 @ http://www.marketdataforecast.com/market-reports/europe-antibodies-market-1179/ Europe Antibodies Industry is driven by innovative products, increasing rate of adoption to therapeutic antibodies in cost-sensitive Industrys, rise in chronic illnesses due to population shift and increasing longevity, quick approval for breakthrough therapies by regulatory authorities, and adoption of diagnostic antibodies. High cost of treatment and side effects associated with antibodies treatment are the restraints that are affecting the growth of the Industry. Based on product type, the Industry is segmented into Monoclonal Antibodies, Polyclonal Antibodies, and Anti-body drug complexes. The monoclonal antibodies are further segmented into Murine, Chimeric, Humanized, and Human. The polyclonal antibodies are further categorized into Type I, Type II, Type III, Type IV, Type V, Type VI, Type VII, Type VIII. The Antibody-Drug Complexes are further segmented into Immunogen Technology, Seattle Genetics Technology, and Immunomedics Technology. Free sample of the report is available @ http://www.marketdataforecast.com/market-reports/europe-antibodies-market-1179/request-sample Based on Indication, the Industry is segmented into Cancer, Auto immune diseases, Infectious diseases, cardiovascular diseases, and CNS disorders, others (Inflammatory, Microbial Diseases, & Other). Based on end users, the Industry is segmented into Hospitals/Clinics, Research institute, Diagnostics laboratories. Based on Application, the Industry is segmented into Medical, Experimental. The Experimental segment is further categorized into Western blot, ELISA, Radioimmune Assays, immunofluorescence, others (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry).Based on Geography, the Europe Antibodies Industry is analysed under various regions namely U.K, Germany, France, Italy and Spain. Some of the Key players operating in Europe Antibodies Industry are Merck KGaA, Novartis AG, Pfizer Inc., ThermoFisher Scientific Inc., Eli Lilly and company, BioMerieux, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Qiagen N.V. Key Points from Table of Contents Overview
Drivers, Restraints, Opportunities, and Challenges Analysis (DROC) Europe Antibodies Industry: Segmentation
Geographical Analysis
Strategic Analysis
Industry Leaders' Analysis Competitive Landscape About Us: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions. Contact: Abhishek Shukla Sales Manager (International Business Development) Market Data Forecast Direct Line: +1-888-702-9626 Mobile: +91 998 555 0206 Mail:abhishek@marketdataforecast.com
Like it? Share it!More by this author |